Project Grant R01AI185558
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$431K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $365,608 to Duke University to conduct research on human cytomegalovirus (HCMV) infection at the maternal-fetal interface. The primary objectives are to: 1) Determine if the transcription factor DUX4 and its target gene TRIM43 restrict HCMV replication in trophoblast organoids, and 2) Define the impacts of HCMV-induced...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Medical College of Wisconsin, Inc. (MCW) to study the impact of human cytomegalovirus (HCMV) infection on the development of human neural tissues. The $682,879 award, effective from January 24, 2025 to December 31, 2029, aims to: (1) define the transcriptional and cellular disruptions to developing human neural cells caused by...
This Project Grant award of $290,132.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define how the cellular protein Stem-Loop Binding Protein (SLBP) promotes the infectivity of Human Cytomegalovirus (HCMV). The research will: 1) Determine the function of SLBP required to enhance HCMV infectivity, 2) Characterize differences in the secretome (secreted factors) during HCMV infection with and without SLBP, and 3)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $232,415.00 to the University of California, Davis to investigate the use of a monoclonal antibody targeting the cytomegalovirus (CMV)-encoded IL-10 protein as a prophylactic treatment to prevent primary CMV infection. The goal is to develop a novel approach to preventing congenital CMV disease, which currently lacks...
This $134,269 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research led by the Trustees of Tufts College, doing business as Tufts University School of Medicine, to characterize the structure and antigenic properties of the human cytomegalovirus (HCMV) glycoprotein B (GB) in its prefusion state. The research aims to identify and isolate novel...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $683,995.00 to fund research to develop novel therapeutics targeting human cytomegalovirus (CMV) infections. The research focuses on characterizing the mechanism of action and optimizing a series of N-arylpyrimidinamine (NAPA) compounds that demonstrated potent anti-CMV activity in a high-throughput screening assay....
This Project Grant award, with a total funding of $598,664, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to investigate the differences in CD4+ and CD8+ T cell responses between infants with congenital cytomegalovirus (CCMV) infection and those with postnatal CMV infection. The key objectives are to: 1) identify pathways inhibiting Th1 cell responses after...
This Project Grant award of $832,910 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to identify immune signatures that predict cytomegalovirus (CMV) disease risk in orthotopic liver transplant recipients. The research aims to characterize the neutralizing and non-neutralizing antibody response, map the CMV-specific B cell repertoire, and quantify and analyze the CMV-specific T cell repertoire to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,821,515 to the University of California, Los Angeles (UCLA) to support research aimed at harnessing cytomegalovirus (CMV) to improve control of HIV-1 infection. Specifically, the project will focus on optimizing a panel of bi-specific chimeric antigen receptors (CARs) that recognize both CMV and HIV-1...